Evidence map›Paper›PMID 39377379›Full record

ArticleCurrent medicinal chemistry2025

Design, Synthesis, Docking Studies, and Biological Activity of Novel Analogs of Cyclophosphamide as Potential Anticancer Agents.

Khodayar Gholivand, Soobieh Alemi Rostami, Marzie Sabaghian, Sanam Sadeghi-Mohammadi, Azam Babaei, Rahime Eshaghi Malekshah, Hossein Naderi-Manesh

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Khodayar GholivandDepartment of Chemistry, Faculty of Science, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran.
Soobieh Alemi RostamiDepartment of Chemistry, Faculty of Science, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran.
Marzie SabaghianDepartment of Chemistry, Faculty of Science, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran.
Sanam Sadeghi-MohammadiATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Azam BabaeiDepartment of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Rahime Eshaghi MalekshahDepartment of Medicinal and Applied Chemistry, Kaohsiung Medical University, Taiwan.
Hossein Naderi-ManeshDepartment of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to present the synthesis and characterization of four novel analogs of cyclophosphamide (2, 3, 4, 7) and their related precursors (1, 5, 6) and assess their anticancer activity against breast cancerous (MCF-7) and normal (HUVEC) cells.

methodsNotably, 2-(bis(2-chloroethyl)amino)-1,3,2-diazaphospholidine 2-oxide (2) and 2-(bis(2-hydroxyethyl)amino)-1,3,2-diazaphospholidine 2-oxide (7) exhibited concentration- dependent cytotoxicity against the MCF-7 cell line, with IC

resultsAnnexin V/PI staining and ROS assays demonstrated reduced cell viability and mitochondrial dysfunction. in silico studies involving DFT-D optimization and Molegro virtual docking against B-DNA dodecamer and STAT3 receptors revealed enhanced interactions for certain compounds compared to cyclophosphamide.

conclusionImportantly, the in silico and in vitro results corroborated each other, supporting the potential anticancer efficacy of these novel analogs.

Indexed as

Antineoplastic AgentsCyclophosphamideDrug DesignMolecular Docking SimulationApoptosisCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMCF-7 CellsMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsCyclophosphamideanticancerbreast cancerCyclophosphamidedocking studiesMTT assayROS assay.

Identifiers

PMID39377379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.